DOCSLIB.ORG

Allergen Immunotherapy: a Practice Parameter Third Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Allergen Immunotherapy: a Practice Parameter Third Update Task force report Allergen immunotherapy: A practice parameter third update Chief Editors: Linda Cox, MD, Harold Nelson, MD, and Richard Lockey, MD Workgroup Contributors: Christopher Calabria, MD, Thomas Chacko, MD, Ira Finegold, MD, Michael Nelson, MD, PhD, and Richard Weber, MD Task Force Reviewers: David I. Bernstein, MD, Joann Blessing-Moore, MD, David A. Khan, MD, David M. Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher Randolph, MD, Diane E. Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, and Dana Wallace, MD Key words: Allergy immunotherapy, subcutaneous immunotherapy, These parameters were developed by the Joint Task Force on sublingual immunotherapy, allergic rhinitis, asthma, Hymenoptera, Practice Parameters, representing the American Academy of atopic dermatitis, anaphylaxis, epinephrine, b-blockers, angioten- Allergy, Asthma & Immunology (AAAAI); the American Col- sin-converting enzyme inhibitor, epicutaneous immunotherapy, in- lege of Allergy, Asthma & Immunology (ACAAI); and the Joint tralymphatic immunotherapy, nasal immunotherapy Council of Allergy, Asthma & Immunology. The American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology have jointly accepted responsibility for establishing ‘‘Allergen immunotherapy: A practice parameter third update.’’ This is a complete and com- Disclosure of potential conflict of interest: L. Cox is a consultant for Genentech/Novartis, Hollister-Stier, and Stallergenes; is a speaker for Novartis; has received research prehensive document at the current time. The medical environ- support from Stallergenes; is on the Board of Directors for the American Board of ment is a changing environment, and not all recommendations Allergy and Immunology; and is on the US Food and Drug Administration (FDA)’s will be appropriate for all patients. Because this document Allergenic Product Advisory Committee. H. Nelson is a consultant for Merck and incorporated the efforts of many participants, no single individ- Planet Biopharmaceuticals, is a Data and Safety Monitoring Board member of DBV Technologies, and has received research support from ALK-Abello. M. Nelson has re- ual, including those who served on the Joint Task Force, is ceived research support from the Department of Defense, is a speaker for the American authorized to provide an official AAAAI or ACAAI interpretation College of Allergy, Asthma & Immunology (ACAAI), and is a member of the FDA’s of these practice parameters. Any request for information about or Advisory Committee on Allergic Products. R. Weber is on the speakers’ bureau for As- an interpretation of these practice parameters by the AAAAI or traZeneca and Genentech, has received research support from Novartis and Glaxo- the ACAAI should be directed to the Executive Offices of the SmithKline, and is Committee Chair of the ACAAI. D. I. Bernstein is a consultant and on the advisory board for ALK America, is on the advisory board for Merck, AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & and has received research support from Merck and Schering-Plough. J. Blessing- Immunology. These parameters are not designed for use by Moore is a speaker for Merck-Schering/AstraZeneca, Novartis, TEVA, and Meda pharmaceutical companies in drug promotion. A current list of Alcon and has received research support from Meda. D. A. Khan is a speaker for As- published practice parameters of the Joint Task Force on Practice traZeneca and Merck, has received research support from the Vanberg Family Foun- dation and the Sellars Family Foundation, is Conjoint Board Review Chair for the Parameters for Allergy and Immunology can be found in Table E1 ACAAI, and is a past president of the Texas Allergy, Asthma and Immunology Society. in this article’s Online Repository at www.jacionline.org. D. M. Lang is a speaker and consultant for GlaxoSmithKline; is a speaker for Astra- Zeneca, Merck, TEVA, Sanofi-Aventis, and Genentech/Novartis; and has received re- search support from Genentech/Novartis. R. A. Nicklas is a fellow for the ACAAI. J. CONTRIBUTORS Oppenheimer is a consultant and has provided lectures for AstraZeneca, Merck, and The Joint Task Force has made a concerted effort to acknowl- GlaxoSmithKline; and has received research support from AstraZeneca, Merck, Glax- oSmithKline, and Genentech. J. M. Portnoy is a speaker for Phadia, Merck, and CSL edge all contributors to this parameter. If any contributors have Behring; has received research support from the US Department of Housing and Urban been excluded inadvertently, the Task Force will ensure that Development; and is a board member of the ACAAI board of regents. S. L. Spector has appropriate recognition of such contributions is made subse- received research support from Genentech, GlaxoSmithKline, Schering-Plough, quently. The Joint Task Force gratefully acknowledges the Aventis, Novartis, Pharmaxis, Boehringer Ingelheim, AstraZeneca, Johnson & John- son, Xyzal, Alcon, Centocor, Sepracor, UCB, Amgen, Capnia, and IVAX. S. Tilles AAAAI Board of Directors and the ACAAI Board of Regents is a speaker for Alcon; is on the advisory board for ALK, Ista, Merck, and Stallergenes; for their review and support of this document. has received research support from Alcon, Amgen, Amphastar, Astellas, Boehringer The authors and editors gratefully acknowledge Susan Grupe Ingelheim, Ception, Genentech, Icagen, MAP Pharma, MEDA, Merck, Novartis, Rox- and Jessica Karle for their administrative assistance. ane, and Sepracor; is Associate Editor of Allergy Watch and Annals of Allergy; and is a task force member for the Joint Task Force for Practice Parameters. D. Wallace is a speaker and advisor for Alcon, is a speaker for Merck and Sanofi-Aventis, and is President-Elect of the ACAAI. The rest of the authors have declared that they have CHIEF EDITORS no conflict of interest. Linda Cox, MD Received for publication September 18, 2010; accepted for publication September 23, Department of Medicine Nova Southeastern University 2010. College of Osteopathic Medicine Available online December 3, 2010. Reprint requests: Joint Council of Allergy, Asthma & Immunology, 50 N Brockway St, Davie, Florida #3-3, Palatine, IL 60067. E-mail: [email protected]. 0091-6749/$36.00 Richard Lockey, MD Ó 2010 American Academy of Allergy, Asthma & Immunology Division of Allergy and Immunology doi:10.1016/j.jaci.2010.09.034 Department of Internal Medicine S1 S2 COX ET AL J ALLERGY CLIN IMMUNOL JANUARY 2011 University of South Florida College of Medicine and James A. University of Missouri–Kansas City School of Medicine Haley Veterans’ Hospital Kansas City, Missouri Tampa, Florida Christopher Randolph, MD Harold Nelson, MD Yale University Department of Medicine New Haven, Connecticut National Jewish Health Diane E. Schuller, MD Denver, Colorado Department of Pediatrics Pennsylvania State University WORK GROUP MEMBERS Milton S. Hershey Medical College Hershey, Pennsylvania Christopher Calabria, MD Glen Burnie, Maryland Sheldon L. Spector, MD Department of Medicine Thomas Chacko, MD UCLA School of Medicine Roswell, Georgia Los Angeles, California Ira Finegold, MD Stephen A. Tilles, MD New York, New York Department of Medicine Michael Nelson, MD, PhD University of Washington School of Medicine Washington, DC Redmond, Washington Richard Weber, MD Dana V. Wallace, MD Denver, Colorado Department of Medicine Nova Southeastern University Davie, Florida JOINT TASK FORCE REVIEWERS David Bernstein, MD Department of Medicine and Environmental Health INVITED REVIEWERS University of Cincinnati College of Medicine Don Aaronson, MD, JD, MPH Cincinnati, Ohio Chicago, Illinois David A. Khan, MD Desiree Larenas-Linnemann, MD Department of Internal Medicine Mexico city, Mexico University of Texas Southwestern Medical Center Bryan Leatherman, MD Dallas, Texas Gulfport, Mississippi Joann Blessing-Moore, MD Sandra Y. Lin, MD Departments of Medicine and Pediatrics Johns Hopkins Department of Otolaryngology–Head & Neck Stanford University Medical Center Surgery Department of Immunology Baltimore, Maryland Palo Alto, California Oral and sublingual immunotherapy for food hypersensitivity David M. Lang, MD Wesley Burkes, MD Allergy/Immunology Section Duke University Division of Medicine Allergy and Immunology Fellowship Raleigh, North Carolina Training Program Venom hypersensitivity Cleveland Clinic Foundation Cleveland, Ohio David Golden, MD Baltimore, Maryland Richard A. Nicklas, MD Department of Medicine Theodore M. Freeman, MD George Washington Medical Center Helotes, Texas Washington, DC Allergen extract section John Oppenheimer, MD Derek Constable, PhD Department of Internal Medicine Spokane, Washington New Jersey Medical School Robert Esch, PhD Pulmonary and Allergy Associates Lenoir, North Carolina Morristown, New Jersey Larry Garner, CPT, BA Jay M. Portnoy, MD Spokane, Washington Section of Allergy, Asthma & Immunology The Children’s Mercy Hospital Richard Lankow, PhD Department of Pediatrics Round Rock, Texas J ALLERGY CLIN IMMUNOL COX ET AL S3 VOLUME 127, NUMBER 1 Greg Plunkett, PhD Extract Manufacturers were invited through their organization, Round Rock, Texas the Allergenic Products Manufacturing Association, to review and comment on the allergen extract section. All of these in- Ronald Rabin, MD vited reviewers who contributed to the document are acknowl- Rockville, Maryland edged for their efforts within the particular section that they reviewed. In addition, the draft was posted on the ACAAI and
Load more

Recommended publications
  • Food Allergy Outline
    Allergy Evaluation-What it all Means & Role of Allergist Sai R. Nimmagadda, M.D.. Associated Allergists and Asthma Specialists Ltd. Clinical Assistant Professor Of Pediatrics Northwestern University Chicago, Illinois Objectives of Presentation • Discuss the different options for allergy evaluation. – Skin tests – Immunocap Testing • Understand the results of Allergy testing in various allergic diseases. • Briefly Understand what an Allergist Does Common Allergic Diseases Seen in the Primary Care Office • Atopic Dermatitis/Eczema • Food Allergy • Allergic Rhinitis • Allergic Asthma • Allergic GI Diseases Factors that Influence Allergies Development and Expression Host Factors Environmental Factors . Genetic Indoor allergens - Atopy Outdoor allergens - Airway hyper Occupational sensitizers responsiveness Tobacco smoke . Gender Air Pollution . Obesity Respiratory Infections Diet © Global Initiative for Asthma Why Perform Allergy Testing? – Confirm Allergens and answer specific questions. • Am I allergic to my dog? • Do I have a milk allergy? • Have I outgrown my allergy? • Do I need medications? • Am I penicillin allergic? • Do I have a bee sting allergy Tests Performed in the Diagnostic Allergy Laboratory • Allergen-specific IgE (over 200 allergen extracts) – Pollen (weeds, grasses, trees), – Epidermal, dust mites, molds, – Foods, – Venoms, – Drugs, – Occupational allergens (e.g., natural rubber latex) • Total Serum IgE (anti-IgE; ABPA) • Multi-allergen screen for IgE antibody Diagnostic Allergy Testing Serological Confirmation of Sensitization History of RAST Testing • RAST (radioallergosorbent test) invented and marketed in 1974 • The suspected allergen is bound to an insoluble material and the patient's serum is added • If the serum contains antibodies to the allergen, those antibodies will bind to the allergen • Radiolabeled anti-human IgE antibody is added where it binds to those IgE antibodies already bound to the insoluble material • The unbound anti-human IgE antibodies are washed away.
    [Show full text]
  • Allergen Regulations 105 Cmr 590.000
    ALLERGEN REGULATIONS 105 CMR 590.000: STATE SANITARY CODE CHAPTER X – MINIMUM SANITATION STANDARDS FOR FOOD ESTABLISHMENTS (1) ADD new definition in 105 CMR 590.002(B): Major Food Allergen means: (1) Milk, eggs, fish (such as bass, flounder, or cod), crustaceans (such as crab, lobster, or shrimp), tree nuts (such as almonds, pecans, or walnuts), wheat, peanuts, and soybeans; and (2) A FOOD ingredient that contains protein derived from a FOOD named in subsection (1). "Major food allergen" does not include: (a) Any highly refined oil derived from a FOOD specified in subsection (1) or any ingredient derived from such highly refined oil; or (b) Any ingredient that is exempt under the petition or notification process specified in the federal Food Allergen Labeling and Consumer Protection Act of 2004 (Public Law 108-282). (2) Amend the definitions of “menu” and “menu board” in 590.002(B) as follows: Menu means a printed list or pictorial display of a food item or items and their price(s) that are available for sale from a food establishment, and includes menus distributed or provided outside of the establishment. Menu Board means any list or pictorial display of a food item or items and their price(s) posted within or outside a food establishment. (3) Amend as follows 105 CMR 590.003(B) (Management and Personnel – federal 1999 Food Code Chapter 2) (B) FC 2-102.11 Demonstration … The areas of knowledge include: . (17) No later than February 1, 2011: (a) Describing FOODS identified as MAJOR FOOD ALLERGENS and describing the symptoms that MAJOR FOOD ALLERGENS could cause in a sensitive individual who has an allergic reaction; and (b) Ensuring that employees are properly trained in food allergy awareness as it relates to their assigned duties.
    [Show full text]
  • Food Allergen Labeling Exemption Petitions and Notifications: Guidance for Industry
    Contains Nonbinding Recommendations Food Allergen Labeling Exemption Petitions and Notifications: Guidance for Industry Additional copies are available from: Office of Food Additive Safety, HFS-205 Center for Food Safety and Applied Nutrition Food and Drug Administration 5001 Campus Drive College Park, MD 20740 (Tel) 240-402-1200 http://www.fda.gov/FoodGuidances You may submit either electronic or written comments regarding this guidance at any time. Submit electronic comments to http://www.regulations.gov. Submit written comments on the guidance to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register. U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition June 2015 Petitions and Notifications Guidance Page 1 of 18 Contains Nonbinding Recommendations Table of Contents I. Introduction II. Statutory Authority III. Recommendations for Preparing Submissions IV. Additional Information for Petitions V. Additional Information for Notifications VI. Appendices Petitions and Notifications Guidance Page 2 of 18 Contains Nonbinding Recommendations Food Allergen Labeling Exemption Petitions and Notifications Guidance for Industry This guidance represents the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance.
    [Show full text]
  • TITLE of STUDY Milk Allergy Is a Very Common Problem in Children. Milk
    TITLE OF STUDY Milk Desensitization and Induction of Tolerance in Children Milk Allergy is a very common problem in children. Milk-induced symptoms effect up-to 20% of children, with detrimental effects on nutrition during critical periods of growth. Moreover, approximately 2-5% of children make IgE antibodies against cow’s milk, which are responsible for severe allergic reactions and anaphylaxis. Milk is the second most common food causing life-threatening anaphylaxis in North America and Europe, and the most common food to cause life- threatening symptoms world-wide. Due to the ubiquitous nature of dairy products in our diet, milk is extremely difficult to avoid. Treatment of milk allergy is currently based on strict avoidance, and patients must carry injectable adrenalin (e.g. Epipen). Our study will assess a novel and potentially life-changing therapy, by actively treating milk allergy with Oral Immunotherapy. This may allow patients to safely consume dairy products. Treatment with oral-immunotherapy has been piloted in the USA and Europe, but there is no current research into milk- immunotherapy in Canada, depriving our population of a potential cure for this very common problem. We propose to perform a well-defined clinical study, using proper control groups and immunological measures to properly understand the ideal patients and the safest and most efficacious methodologies. If successful, this study will clearly increase the margin of safety for children and young adults who suffer from life-threatening milk allergy. It can also increase the consumption of dairy products within this population, providing nutritional benefits including improved bone mineralization and growth.
    [Show full text]
  • Peptide Allergen Immunotherapy: a New Perspective in Olive-Pollen Allergy
    pharmaceutics Review Peptide Allergen Immunotherapy: A New Perspective in Olive-Pollen Allergy David Calzada 1,†, Lucía Cremades-Jimeno 1,†, María López-Ramos 1 and Blanca Cárdaba 1,2,* 1 Immunology Department, IIS-Fundación Jiménez Díaz-UAM, 28040 Madrid, Spain; [email protected] (D.C.); [email protected] (L.C.-J.); [email protected] (M.L.-R.) 2 Ciber de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Allergic diseases are highly prevalent disorders, mainly in industrialized countries where they constitute a high global health problem. Allergy is defined as an immune response “shifted toward a type 2 inflammation” induced by the interaction between the antigen (allergen) and IgE antibodies bound to mast cells and basophils that induce the release of inflammatory mediators that cause the clinical symptoms. Currently, allergen-specific immunotherapy (AIT) is the only treatment able to change the course of these diseases, modifying the type 2 inflammatory response by an allergenic tolerance, where the implication of T regulatory (Treg) cells is considered essential. The pollen of the olive tree is one of the most prevalent causes of respiratory allergic diseases in Mediterranean countries, inducing mainly nasal and conjunctival symptoms, although, in areas with a high antigenic load, olive-tree pollen may cause asthma exacerbation. Classically, olive-pollen allergy treatment has been based on specific immunotherapy using whole-olive pollen extracts. Citation: Calzada, D.; Despite extracts standardization, the effectiveness of this strategy varies widely, therefore there is a Cremades-Jimeno, L.; López-Ramos, need for more effective AIT approaches.
    [Show full text]
  • An Update on Food Allergen Management and Global Labeling
    An Update on Food Allergen Management and Global Labeling Regulations A Thesis SUBMITTED TO THE FACULTY OF UNIVERSITY OF MINNESOTA BY Xinyu Diao IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE Advisor: David Smith, Ph.D. Aug 2017 © {Xinyu Diao} {2017} Acknowledgements I would like to thank my advisor Dr. David Smith for his guidance and support throughout my Master’s program. With his advice to join the program, my wonderful journey at the University of Minnesota began. His tremendous support and encouragement motivates me to always dream big. I would like to also thank Dr. Jollen Feritg, Dr. Len Marquart and Dr. Adam Rothman for being willing to take their valuable time to serve as my committee members. I am grateful to many people whose professional advice is invaluable over the course of this project. I would like to take this opportunity to show appreciation for Dr. Gerald W. Fry for being a role model for me as having lifetime enthusiasm for the field you study. I wouldn’t be where I am now without the support of my friends. My MGC (Graduate Student Club) friends who came all around the world triggered my initial interest to investigate a topic which has been concerned in a worldwide framework. Finally, I would like to give my most sincere gratitude to my family, who provide me such a precious experience of studying abroad and receiving superior education. Thank you for your personal sacrifices and tremendous support when I am far away from home. i Dedication I dedicate this thesis to my father, Hongquan Diao and my mother, Jun Liu for their unconditional love and support.
    [Show full text]
  • Allergen Immunotherapy in Asthma; What Is New? Giovanni Passalacqua*, Anthi Rogkakou, Marcello Mincarini and Giorgio Walter Canonica
    Passalacqua et al. Asthma Research and Practice (2015) 1:6 DOI 10.1186/s40733-015-0006-2 REVIEW Open Access Allergen immunotherapy in asthma; what is new? Giovanni Passalacqua*, Anthi Rogkakou, Marcello Mincarini and Giorgio Walter Canonica Abstract The use and role of allergen immunotherapy (AIT) in asthma is still a matter of debate, and no definite recommendation about this is made in guidelines, both for the subcutaneous and sublingual routes. This is essentially due to the fact that most controlled randomised trials were not specifically designed for asthma, and that objective measures of pulmonary function were only occasionally considered. Nonetheless, in many trials, favourable results in asthma (symptoms, medication usage, bronchial reactivity) were consistently reported. There are also several meta analyses in favour of AIT, although their validity is limited by a relevant methodological heterogeneity. In addition to the crude clinical effect, a disease modifying action of AIT (prevention of asthma onset and long-lasting effects) have been reported. The safety is an important aspect to consider in asthma. Fatalities were rare: in Europe no fatality was reported in the last three decades, as in the United States in the last 4 years. Based on previous surveys, and common sense, uncontrolled asthma is still recognized as the most important risk factor for severe adverse events. On the contrary, there is no evidence that AIT can worsen or induce asthma. According to the available evidence, AIT can be safely used as add-on treatment when asthma is associated with rhinitis (a frequent condition), provided that asthma is adequately controlled by pharmacotherapy.
    [Show full text]
  • Involvement of Haptens in Allergic and Non-Allergic Hypersensitivity
    Polish J. of Environ. Stud. Vol. 18, No 3 (2009), 325-330 Review Involvement of Haptens in Allergic and Non-Allergic Hypersensitivity E. Kucharska1*, J. Bober2**, L. Jędrychowski3*** 1Department of Human Nutrition, Faculty of Food Sciences and Fisheries, West-Pomeranian University of Technology, Papieża Pawła VI no. 3, 71-459 Szczecin, Poland 2Department of Medical Chemistry, Pomeranian Medical University, Powstańców Wlkp. 72, 70-111 Szczecin, Poland 3Institute of Animal Reproduction and Food Research of the Polish Academy of Sciences in Olsztyn, Tuwima 10, 10-747 Olsztyn, Poland Received: 7 July 2008 Accepted: 11 December 2008 Abstract The environment is used as a broad umbrella term for all sources of allergens which may cause allergic hypersensitive reaction of the immune system of humans. Westernization of life leads to increased average consumption of food additives (natural and xenobiotics) – starting from over 5kg (10lbs) annually with a strong tendency to intensify. Modern technologies of food production often employ substances improving quality, texture, colour, taste, acidity or alkalinity. Haptens present in food or drugs, penetrating organism via gastrointestinal tract, may be responsible for symptoms not only in the gastrointestinal tract itself, but also in peripheral organs. Mechanisms of hapten action within human body are different – they include reactions when the immune system is involved (allergic hypersensitivity) and not involved (food intolerance also known as non-allergic hypersensitivity). Food intolerance is a more frequent phenomenon diagnosed in 20-50% of cases; food allergy affecting 6-8% children and 1-2% adults. Our work elucidates mechanisms of hypersensi- tivity responses to haptens, and characterizes major haptens applied as food additives.
    [Show full text]
  • Allergen Testing AHS – G2031
    Corporate Medical Policy Allergen Testing AHS – G2031 File Name: allergen_testing Origination: 01/01/2019 Last CAP Review: 11/2020 Next CAP Review: 11/2021 Last Review: 11/2020 Description of Procedure or Service Allergic disease is characterized by inappropriate or exaggerated immune reactions to foreign antigens (allergens) that are generally innocuous to most people, but when introduced into a genetically-predisposed individual, elicit a hypersensitivity reaction (R. Hamilton, 2020). Hypersensitivity reactions can be classified into four types, two of which are associated with allergy, type I immediate immunoglobulin E (IgE) reactions and type IV T cell mediated reactions (K.-L. Chang & J. C. Guarderas, 2018). Type I reactions involve the formation of IgE antibodies specific to the allergen. When the subject is re-exposed to that allergen, the allergen binds multiple IgE molecules, resulting in the release of an array of inflammatory mediators, including histamines, that precipitate the symptoms of allergic disease (R. Hamilton, 2018). Allergen testing in serum is designed to detect the presence of allergen-specific IgE. A positive test for allergen-specific IgE confirms the presence of the antibody only. Actual reactivity must be determined by history or supervised challenge (Kowal & DuBuske, 2020). Several diagnostic procedures have been developed to elicit and assess hypersensitivity reactions including epicutaneous, intradermal, patch, bronchial, exercise, and ingestion challenge tests (Bernstein et al., 2008). ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician. Policy BCBSNC will provide coverage for allergen testing when it is determined the medical criteria or reimbursement guidelines below are met.
    [Show full text]
  • Tolerance to Allergens: How It Develops and How It Can Be Induced
    Session 2101 Plenary: Immunotherapy: Mechanism, Outcomes and Markers Tolerance to Allergens: How it Develops and How it Can be Induced Cezmi A. Akdis, MD Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland Corresponding author: Cezmi A. Akdis, MD Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos Address E-mail: [email protected] Tel.: + 41 81 4100848 Fax: + 41 81 4100840 Acknowledgments: The authors' laboratories are supported by the Swiss National Foundation grant 320030_132899 and Christine Kühne Center for Allergy Research and Education (CK-CARE). ABSTRACT The induction of immune tolerance and specific immune suppression are essential processes in the control of immune responses. Allergen immunotherapy induces early desensitization and peripheral T cell tolerance to allergens associated with development of Treg and Breg cells, and downregulation of several allergic and inflammatory aspects of effector subsets of T cells, B cells, basophils, mast cells and eosinophils. Similar molecular and cellular mechanisms have been observed in subcutaneous and sublingual AIT as well as natural tolerance to high doses of allergen exposure. In allergic disease, the balance between allergen-specific Treg and disease-promoting T helper 2 cells (Th2) appears to be decisive in the development of an allergic versus a non-disease promoting or “healthy” immune response against allergen. Treg specific for common environmental allergens represent the dominant subset in healthy individuals arguing for a state of natural tolerance to allergen in these individuals. In contrast, there is a high frequency of allergen-specific Th2 cells in allergic individuals. Treg function appears to be impaired in active allergic disease.
    [Show full text]
  • Allergen Immunotherapy
    Allergen Immunotherapy Introduction This Factsheet is a summary of the various forms of immunotherapy. We focus primarily on food allergies and insect sting allergy (which are the core work of the Anaphylaxis Campaign) but also give some basic information on treatments for allergic rhinitis (hay fever). Some reference is made to treatments for eczema and asthma. Throughout this Factsheet you will see brief medical references given in brackets. Full references are provided at the end. What is allergen immunotherapy? Allergy occurs when a person’s immune system reacts in an inappropriate or exaggerated way to a food or substance that, in the majority of people, causes no symptoms. A food or substance that causes an allergic reaction is called an allergen. Allergen immunotherapy, previously known as desensitisation, is a medical treatment for allergies. The idea is that the patient’s immune system can be ‘trained’ to tolerate the allergen and therefore not cause allergic symptoms. Allergen immunotherapy for hay fever and asthma has been shown to have benefits for many years after stopping the treatment, where treatment has been ongoing for at least 3-5 years. This has not yet been shown for food allergy to date. Research is also underway to assess whether immunotherapy can potentially reduce the risk of the development of asthma and new allergies. There is some evidence that pollen immunotherapy for hay fever reduces the subsequent risk of developing asthma and that therapy to treat one allergy reduces the subsequent risk of developing reactions to other allergens (Des Roches A, 1997; Purello D, 2001; Panjo GB, 2001).
    [Show full text]
  • Youth Confesses Armed Robbery at Boyd's Store Merrill D. Graham To
    ****** CvfTMif Ntwt Ittmt y/Im Sheet* About Our SorvictmM ii Pvt Harry J. Taylor, son ol Mr. and Mrs. Ralph Taylor, Route 3. Holding. Mich., ii now serving in Korea with the 3d Infantry Di- EstablishedJune, 1893 LOWELL, MICH., THURSDAY, JANUARY 21. 1954 Number 38 The IGth March of Dimes is vision. Just starting. It may well 1)0 the The "Rook of the Marne" dl- Poor Vitibitify and Ice Two I^mvell Polio Victims Battle Disease Side by Si(l< vision, which saw bitter fighting Merrill D. Graham most significant one ever held. In the Iron Triangle and at Out- Youth Confesses Blamed for Accidents The announcement of a now pro- post Harry and Jaokson Heights, gram POLIO PREVENTION— Slippery blacktop and poor visi- Is now undergoing Intensive post- To Speak Tuesday with a trial vaccine to be tested Armed Robbery bility from fog Wednesday morn- this year may mean a grim and truce training. ing was responsible for several Taylor, who entered the Army expensive battle soon won. Vic- mishaps and minor accidents on last June, was formerly stationed At B. of T. Dinner tory seems close, but It can only At Boyd's Store highways around this area. Those at Fort Knox, Ky. be reached If we dig down and Police Chief Frank L. Stephens who commute Into Lowell from The annnual meeting of the give. Second Lt. Harold K. Vovllla, announced Wednesday noon thai i other towns and those from here Lowell Board of Trade to be held Give more than ever before. Tuesday, Jan. 20.
    [Show full text]